Patents by Inventor David Selwood

David Selwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10494404
    Abstract: The present invention relates to conjugates of cyclosporin with quinolium mitochondrial targeting groups, and their therapeutic uses.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: December 3, 2019
    Assignee: UCL Business PLC
    Inventors: David Selwood, David Baker, Gyorgy Szabadkai, Michael Roland Duchen, Julia Marie Hill, Justin Neil Darrel Warne
  • Patent number: 10087144
    Abstract: The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition: wherein: V is N or CR3; X is N or CR4; Y is N or CR5; Z is N or CR6; B is —(C?O)R1, a 5- to 10-membered heteroaryl group, or a group L??-NRR?, wherein R and R? are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group; R1 is a 5- to 10-membered heterocyclyl group, or —OR?, wherein R? is a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group, or R1 is a proteinogenic ? amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the ? amino group, which amino acid is optionally esterified at the ? carboxylic acid group with a C1-C6 alkyl group or a C6-C10 aryl group, or R1 is —NR?R??, —NRIV-L??-CONR?R??, or —NRIV-L??-COOR, wherein R, R?, R?? and RIV are the same or different and e
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: October 2, 2018
    Assignee: UCL Business PLC
    Inventors: David Selwood, Adrian Hobbs
  • Publication number: 20180116983
    Abstract: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: Z is OR16 or NR17R18; R16 is H or alkyl; R17 is H or alkyl; R18 is alkyl or cycloalkyl, each of which is optionally substituted by one or more substituents selected from OH, halogen and COOR11; X is a group selected from —C?C—<CH2)p—; —C<R5)?C(R6)—(CH2)q—; and —C(R5)(R6)C(R7)(R8)—(CH2)2—; where each of R5, R6, R7 and R8 is independently II or alkyl, and each of p, q and r is independently 1, 2, 3, 4 or 5; Y is a group selected from: CN; COOR2; CONR3R4; SO2NR9R10; NR12COR13; NR14SO2R15; and a heterocyclic group selected from oxadiazolyl, thiazolyl, iso- thiazolyl, oxazolyl, iso-oxazolyl, pyrazoiyl and it-nidazolyl; where each of R2, R3 and R4 is independently H or alkyl; or R3 and R4 are linked, together with the nitrogen to which they are attached, to form a 5 or 6-membered heterocycloalkyl or heterocycloalkenyl group, said heterocycloalkyl or heterocycloalkenyl group opt
    Type: Application
    Filed: February 12, 2016
    Publication date: May 3, 2018
    Applicant: Canbex Therapeutics Limited
    Inventors: David Selwood, David Baker
  • Patent number: 9908843
    Abstract: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof: (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substituted by one or more OH groups; X is a group selected from —C?C—(CH2)p—; —C(R5)?C(R6)—(CH2)q—; and —C(R5)(R6)C(R7)(R8)—(CH2)r-; where each of R5, R6, R7 and R8 is independently H or alkyl, and each of p, q and r is independently 1, 2, 3, 4 or 5; Y is a group selected from: CN; COOR2; CONR3R4; SO2NR9R10; NR12COR13; NR14SO2R15; and a heterocyclic group selected from oxadiazolyl, thiazolyl, iso-thiazolyl, oxazolyl, iso-oxazolyl, pyrazolyl and imidazolyl; where each of R2, R3 and R4 is independently H or alkyl; or R3 and R4 are linked, together with the nitrogen to which they are attached, to form a 5 or 6-membered heterocycloalkyl or heterocycloalkenyl group, said heterocycloalkyl or heterocycloalkenyl group optionally containing one or more further groups selected from O, N, CO an
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: March 6, 2018
    Assignee: CANBEX THERAPEUTICS LIMITED
    Inventor: David Selwood
  • Publication number: 20180021303
    Abstract: The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 25, 2018
    Inventors: David Selwood, David Baker
  • Publication number: 20170349632
    Abstract: The present invention relates to conjugates of cyclosporin with quinolium mitochondrial targeting groups, and their therapeutic uses.
    Type: Application
    Filed: August 19, 2015
    Publication date: December 7, 2017
    Inventors: David Selwood, David Baker, Gyorgy Szabadkai, Michael Roland Duchen, Julia Marie Hill, Justin Neil Darrel Warne
  • Publication number: 20170267726
    Abstract: A cyclosporin derivative which is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a viral infection: wherein: A represents B represents methyl or ethyl, R2 represents ethyl or isopropyl, R4 represents —CH2CH(CH3)CH3, —CH2CH(CH3)CH2CH3, —CH(CH3)CH3 or —CH(CH3)CH2CH3, and either (a) one of R1 and R1* represents hydrogen and the other represents methyl, and R3 represents -L3-G3, or (b) one of R1 and R1* represents hydrogen and the other represents -L1-G1, and R3 represents H, wherein L1 and L3 represent a direct bond, a C1-C6 alkylene group or a C2-C6 alkenylene group; and G1 and G3 represent a hydrogen atom, a —COOR? group, or a phenyl moiety which is unsubstituted or substituted by one, two or three substituents selected from a halogen atom, a —COOR? group, a —CONR?R? group, a hydroxyl group, a C1-C6 alkyl group and a C1-C6 alkoxy group, wherein R? and R? are the same or different and represent hydrogen or a C1-C6 alkyl group,
    Type: Application
    Filed: May 30, 2017
    Publication date: September 21, 2017
    Inventors: Greg Towers, David Selwood, Jane Rasaiyaah
  • Patent number: 9682924
    Abstract: The present invention relates to a compound of formula (I) in crystalline form, wherein said compound is in the form of the free base or a pharmaceutically acceptable salt thereof, or a solvate of the free base or salt form thereof. The invention also relates to a pharmaceutical composition containing said crystalline form as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline form.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: June 20, 2017
    Assignee: CANBEX THERAPEUTICS LIMITED
    Inventor: David Selwood
  • Publication number: 20170066722
    Abstract: The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition: wherein: V is N or CR3; X is N or CR4; Y is N or CR5; Z is N or CR6; B is —(C?O)R1, a 5- to 10-membered heteroaryl group, or a group -L??-NRR?, wherein R and R? are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group; R1 is a 5- to 10-membered heterocyclyl group, or —OR?, wherein R? is a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group, or R1 is a proteinogenic ? amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the ? amino group, which amino acid is optionally esterified at the ? carboxylic acid group with a C1-C6 alkyl group or a C6-C10 aryl group, or R1 is —NR?R??, —NRIV-L??-CONR?R??, or —NRIV-L??-COOR, wherein R, R?, R?? and RIV are the same or different and ea
    Type: Application
    Filed: November 18, 2016
    Publication date: March 9, 2017
    Applicant: UCL Business PLC
    Inventors: David Selwood, Adrian Hobbs
  • Publication number: 20160304441
    Abstract: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof : (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substituted by one or more OH groups; X is a group selected from —C?C—(CH2)p—; —C(R5)?C(R6)—(CH2)q—; and —C(R5)(R6)C(R7)(R8)—(CH2)r—; where each of R5, R6, R7 and is independently II or alkyl, and each of p, q and r is independently 1, 2, 3, 4 or 5; Y is a group selected from: CN; COOR2; CONR3R4; SO2NR9R10; NR12COR13; NR14SO2R15; and a heterocyclic group selected from oxadiazolyl, thiazolyl, isothiazolyl, oxazolyl, iso-oxazolyl, pyrazolyl and imidazolyl; where each of R2, R3 and R4 is independently H or alkyl; or R3 and R4 are linked, together with the nitrogen to which they are attached, to form a 5 or 6-membered heterocycloalkyl or heterocycloalkenyl group, said heterocycloalkyl or heterocycloalkenyl group optionally containing one or more further groups selected from O, N, CO and
    Type: Application
    Filed: December 5, 2014
    Publication date: October 20, 2016
    Inventor: David Selwood
  • Publication number: 20160107984
    Abstract: The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is selected from OH, NHCH2CH2F, NHCH(Me)CH2OH and NHCH2CH2OH; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is phenyl or pyridyl; and B is (CH2)n where n is 0; with the proviso that: (i) when A is phenyl, and Z is OH, X—Y is other than C?C—(CH2)2CO2H, C?C—(CH2)2CO2Me, (CH2)4CO2H. Uses of such compounds as medicaments for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors are provided.
    Type: Application
    Filed: July 27, 2015
    Publication date: April 21, 2016
    Inventors: Masahiro OKUYAMA, David SELWOOD, Cristina VISINTIN, David BAKER, Gareth PRYCE
  • Publication number: 20160002299
    Abstract: A cyclosporin derivative which is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a viral infection: wherein: A represents (F(II)) or (F(III)) B represents methyl or ethyl, R2 represents ethyl or isopropyl, R4 represents —CH2CH(CH3)CH3, —CH2CH(CH3)CH2CH3, —CH(CH3)CH3 or —CH(CH3)CH2CH3, and either (a) one of R1 and R1* represents hydrogen and the other represents methyl, and R3 represents —L3-G3, or (b) one of R1 and R1* represents hydrogen and the other represents and R3 represents H, wherein L1 and L3 represent a direct bond, a C1-C6 alkylene group or a C2-C6 alkenylene group; and G1 and G3 represent a hydrogen atom, a —COOR? group, or a phenyl moiety which is unsubstituted or substituted by one, two or three substituents selected from a halogen atom, a —COOR? group, a —CONR?R? group, a hydroxyl group, a C1-C6 alkyl group and a C1-C6 alkoxy group, wherein R? and R? are the same or different and represent hydrogen or a C1-C6 alkyl group, prov
    Type: Application
    Filed: March 3, 2014
    Publication date: January 7, 2016
    Inventors: Greg Towers, David Selwood, Jane Rasaiyaah
  • Publication number: 20150353476
    Abstract: The present invention relates to a compound of formula (I) in crystalline form, wherein said compound is in the form of the free base or a pharmaceutically acceptable salt thereof, or a solvate of the free base or salt form thereof. The invention also relates to a pharmaceutical composition containing said crystalline form as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline form.
    Type: Application
    Filed: January 17, 2014
    Publication date: December 10, 2015
    Inventor: David Selwood
  • Patent number: 9120723
    Abstract: The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is selected from OH, NHCH2CH2F, NHCH(Me)CH2OH and NHCH2CH2OH; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is phenyl or pyridyl; and B is (CH2)n where n is 0; with the proviso that: (i) when A is phenyl, and Z is OH, X—Y is other than C?C—(CH2)2CO2H, C?C—(CH2)2CO2Me, (CH2)4CO2H. Uses of such compounds as medicaments for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors are provided.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: September 1, 2015
    Assignee: CANBEX THERAPEUTICS LIMITED
    Inventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
  • Patent number: 9024067
    Abstract: The present invention relates to a process for preparing a compound of formula wherein: R2 is cycloalkyl or alkyl, each of which may be optionally substituted; Y is —CONR3R4, —CN or CO2R5; R3, R4 and R5 are each independently H or alkyl; n is 1 to 6; wherein said process comprising the steps of: (i) treating a compound of formula (IV), where R1 is alkyl, with a compound of formula (V) and forming a compound of formula (IIIb); (ii) treating said compound of formula (IIIb) with a compound of formula (I1) to form a compound of formula (I).
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: May 5, 2015
    Assignee: Canbex Therapeutics Limited
    Inventor: David Selwood
  • Publication number: 20140357569
    Abstract: A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R1 and R1* represents hydrogen and the other represents methyl, R2 represents ethyl or isopropyl, R3 represents hydrogen or methyl, and R4 represents —CH2CH(CH3)CH3, —CH2CH(CH3)CH2CH3, —CH(CH3)CH3 or —CH(CH3)CH2CH3.
    Type: Application
    Filed: February 28, 2014
    Publication date: December 4, 2014
    Applicant: UCL Business PLC
    Inventors: David Selwood, Martin Crompton
  • Publication number: 20130123356
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof,
    Type: Application
    Filed: October 18, 2012
    Publication date: May 16, 2013
    Applicant: UNIVERSITY COLLEGE LONDON
    Inventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
  • Publication number: 20120283295
    Abstract: The invention provides an indazole derivative of formula (1), or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1, R2, R3 and R4 are as defined herein. The indazole derivatives are capable of blockading voltage dependent sodium channels and they are useful in the treatment or prevention of normal tension glaucoma, multiple sclerosis, a motorneurone disease, stroke, spinal cord injury, Alzheimer's disease, Parkinson's disease or pain.
    Type: Application
    Filed: September 30, 2010
    Publication date: November 8, 2012
    Applicant: University College London
    Inventors: Cristina Garcia Posada, David Selwood, John Garthwaite, David Baker, Lisa Clutterbuck
  • Publication number: 20120269864
    Abstract: The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.
    Type: Application
    Filed: June 11, 2012
    Publication date: October 25, 2012
    Inventors: Haiyan Jia, Ian ZACHARY, Michelle TICKNER, Lili CHENG, Chris CHAPMAN, Katie ELLARD, Basil HARTZOULAKIS, Ashley JARVIS, Rosemary LYNCH, Jamie NALLY, David SELWOOD, Mark STEWART
  • Patent number: 8293796
    Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted by one or more substituents selected from alkyl, COOH, CO2-alkyl, alkenyl, CN, NH2, hydroxy, halo, alkoxy, CF3 and nitro; Y is a polar functional group selected from OH, NO2, CN, COR3, COOR3, NR3R4, CONR3R4, SO3H, SO2—R3, SO2NR3R4 and CF3, where each of R3 and R4 is independently H or a hydrocarbyl group; A is an aryl or heteroaryl group, each of which may be optionally substituted; and B is (CH2)n where n is 0, 1, 2, 3, 4 or 5; with the proviso that: (i) when A is phenyl, n is 0, and Z is OH, X—Y is other than meta-C?—C—(CH2)2CO2H, meta-C?—C—(CH2)2OH, meta-C?C—(CH2)2CO2Me, meta-(CH2)4CO2H, ortho-CH2CO2H, ortho-(CH2)2CO2H and ortho-(CH2)4CO2H; and (ii) when A is phenyl, n is 0, and Z is OMe, X—Y is other than meta-C?
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: October 23, 2012
    Assignee: University College London
    Inventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce